表紙
市場調査レポート

胚細胞腫瘍 : パイプライン分析

Germ Cell Tumors - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 213071
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
胚細胞腫瘍 : パイプライン分析 Germ Cell Tumors - Pipeline Review, H2 2015
出版日: 2015年08月26日 ページ情報: 英文 88 Pages
概要

胚細胞腫瘍は悪性(癌性)または良性(非癌性)の腫瘍で、主に胚細胞(生殖細胞)で構成されています。胚細胞は胎児の中で発達し、男性・女性の生殖系を構成する細胞となります。こうした胚細胞は発達後に人体の正中線を通って、骨盤で卵細胞へ、陰嚢で精巣細胞へと分化します。卵巣腫瘍・精巣腫瘍のほとんどが胚細胞起源のものです。卵巣・精巣はまた生殖腺とも呼ばれます。

当レポートでは、世界各国での胚細胞腫瘍治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

胚細胞腫瘍の概要

治療薬の開発

  • 胚細胞腫瘍向けパイプライン製品:概要
  • 胚細胞腫瘍向けパイプライン製品:比較分析

各企業で開発中の胚細胞腫瘍治療薬

大学/研究機関で研究中の胚細胞腫瘍治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

胚細胞腫瘍治療薬:開発中の製品の一覧(企業別)

胚細胞腫瘍治療薬:研究中の製品の一覧(大学/研究機関別)

肝臓病治療薬の開発に従事している企業

  • AB Science SA
  • ArQule, Inc.
  • Astex Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • MediGene AG
  • Merck & Co., Inc.
  • Novartis AG
  • Philogen S.p.A.
  • Sanofi

胚細胞腫瘍:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • cabazitaxel
  • Cell Therapy 1 for Oncology
  • (dabrafenib mesylate + trametinib dimethyl sulfoxide)
  • G-207
  • guadecitabine
  • pembrolizumab
  • ribociclib
  • Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML
  • Small Molecules to Inhibit Tubulin for Oncology
  • Tetravil
  • tivantinib

胚細胞腫瘍治療薬:最新の薬剤プロファイル

胚細胞腫瘍治療薬:開発が休止状態の製品

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7014IDB

Summary

Global Markets Direct's, 'Germ Cell Tumors - Pipeline Review, H2 2015', provides an overview of the Germ Cell Tumors's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Germ Cell Tumors
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Germ Cell Tumors and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Germ Cell Tumors pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Germ Cell Tumors
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Germ Cell Tumors pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Germ Cell Tumors Overview
  • Therapeutics Development
    • Pipeline Products for Germ Cell Tumors - Overview
    • Pipeline Products for Germ Cell Tumors - Comparative Analysis
  • Germ Cell Tumors - Therapeutics under Development by Companies
  • Germ Cell Tumors - Therapeutics under Investigation by Universities/Institutes
  • Germ Cell Tumors - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Germ Cell Tumors - Products under Development by Companies
  • Germ Cell Tumors - Products under Investigation by Universities/Institutes
  • Germ Cell Tumors - Companies Involved in Therapeutics Development
    • AB Science SA
    • ArQule, Inc.
    • Astex Pharmaceuticals, Inc.
    • GlaxoSmithKline Plc
    • MediGene AG
    • Merck & Co., Inc.
    • Novartis AG
    • Philogen S.p.A.
    • Sanofi
  • Germ Cell Tumors - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cabazitaxel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • G-207 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • guadecitabine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ribociclib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize KIT816 for Aggressive Mastocytosis, Seminoma and AML - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Tubulin for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Tetravil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tivantinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Germ Cell Tumors - Recent Pipeline Updates
  • Germ Cell Tumors - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Germ Cell Tumors, H2 2015
  • Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Germ Cell Tumors - Pipeline by AB Science SA, H2 2015
  • Germ Cell Tumors - Pipeline by ArQule, Inc., H2 2015
  • Germ Cell Tumors - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
  • Germ Cell Tumors - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Germ Cell Tumors - Pipeline by MediGene AG, H2 2015
  • Germ Cell Tumors - Pipeline by Merck & Co., Inc., H2 2015
  • Germ Cell Tumors - Pipeline by Novartis AG, H2 2015
  • Germ Cell Tumors - Pipeline by Philogen S.p.A., H2 2015
  • Germ Cell Tumors - Pipeline by Sanofi, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Germ Cell Tumors Therapeutics - Recent Pipeline Updates, H2 2015
  • Germ Cell Tumors - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Germ Cell Tumors, H2 2015
  • Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top